Search by drug, manufacturer, or indication

Displaying 891 - 900 of 1165

Dysport Therapeutic (abobotulinumtoxina)

Status:

Concluded with an LOI

Manufacturer:

Ipsen Biopharmaceuticals Canada, Inc.

Indication:

Upper Limb Spasticity

Last updated July 17, 2018

Dysport Therapeutic (abobotulinumtoxina)

Status:

Concluded with an LOI

Manufacturer:

Ipsen Biopharmaceuticals Canada, Inc.

Indication:

Cervical dystonia

Last updated July 17, 2018

Hemangiol (propranolol oral solution)

Status:

Concluded with an LOI

Manufacturer:

Pierre Fabre

Indication:

Infantile hemangioma

Last updated July 16, 2018

Rydapt (midostaurin)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Acute Myeloid Leukemia (AML)

Last updated July 5, 2018

Ocaliva (obeticholic acid)

Status:

Concluded with an LOI

Manufacturer:

Intercept Pharma Canada

Indication:

Primary biliary cholangitis

Last updated June 27, 2018

Descovy (emtricitabine/tenofovir alafenamide)

Status:

Concluded without agreement

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

HIV-1 Infection

Last updated June 8, 2018

Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

HIV-1 Infection

Last updated June 6, 2018

Caprelsa (vandetanib)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Medullary Thyroid Cancer

Last updated June 1, 2018

Cerezyme (imiglucerase)

Status:

Concluded without agreement

Manufacturer:

Sanofi Genzyme Canada

Indication:

Gaucher disease

Last updated May 31, 2018

Cerdelga (eliglustat)

Status:

Concluded without agreement

Manufacturer:

Sanofi Genzyme Canada

Indication:

Gaucher disease

Last updated May 31, 2018